Six month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic

Aim of the work: To evaluate the 6-month treatment responses to low dose rituximab (LDR) compared to standard dose rituximab (SDR) in rheumatoid arthritis (RA) patients whose treatments were disrupted due to the pandemic with increased disease activity and to examine the effect of LDR treatment on s...

Full description

Bibliographic Details
Main Authors: Yunus Durmaz, Ilker Ilhanli
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Egyptian Rheumatologist
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1110116421000363